Bio€quity Europe 2017
22-23 May, 2017
Paris, France
Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected Presenting Companies.
Now celebrating its 18th meeting, Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.
EASL – The International Liver Congress 2017
19-23 April, 2017
Amsterdam, The Netherlands
The International Liver Congress™ (ILC) is the annual meeting of the European Association for the Study of the Liver. It is held in April every year.
Asian Pacific Association for the Study of the Liver – APASL Annual Meeting 2017
February 15-19, 2017
Shangai, China
APASL annual meeting has grown as the leading conference focusing on remarkable progress in liver disease, aimed to provide the latest scientific and evidence-based research result that will be applicable to the everyday clinical practice. It provides an excellent opportunity to share and exchange experiences especially from the view of Asian Pacific countries. These elements are essential to pave a way for better development of Hepatology.
A new collaboration studying the impact of FXR function on HBV replications
ENYO Pharma is pleased to announce the initiation of a collaboration with the group of Professor Patrice André (Inserm U1111, Lyon, France) to develop a deeper understanding of how FXR agonists inhibit the replication cycle of Hepatitis B (HBV). In addition to identifying opportunities for new anti-HBV therapeutics, this collaboration will strengthen understanding of the mode of action of EYP001, ENYO’s lead compound. EYP001 is a highly selective FXR modulator that reduces the HBV cccDNA reservoir,
ENYO Pharma SA announces successful initiation of the Phase 1 clinical programme with EYP001, its lead candidate for the treatment of Chronic Hepatitis B Virus infection.
Lyon, December 16, 2016 – ENYO Pharma SA, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1 single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been initiated, and that single dose escalation has been completed. The results have shown that EYP001 is safe and well-tolerated at all doses studied in 46 healthy subjects. The safety and pharmacokinetics (PK) analysis of these first Phase 1 data will be complete by Q2 2017.
Latest Press Release 